Moberg Pharma and Cadila Enter Agreement

Moberg Pharma and Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India, entered a development and license agreement for BUPI, a lozenge formulation of bupivacaine for pain management in oral mucositis patients.

Cadila will conduct a phase III program in India and is granted an exclusive license to commercialize BUPI in India and Africa, with the exception of South Africa. Moberg will receive the rights to use all data generated from the development program outside India and Africa and a royalty on sales in India and Africa. The parties may also agree on a supply agreement for a subsequent commercial phase.

In June 2015, Moberg received a Eurostars grant, which provides co-financing of one phase III study for BUPI in Europe. A phase II study was recently completed with positive results, which supported the efficacy and safety of BUPI. This agreement with Cadila in combination with the Eurostars grant means that Moberg’s investment for phase III trials is substantially reduced.